BioXcel Therapeutics (BTAI) Other financing activities (2017 - 2026)

BioXcel Therapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at $158000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 80.32% year-over-year to $158000.0; the TTM figure through Mar 2026 stood at $648000.0 (down 44.14% YoY), while the FY2025 annual figure was $1.6 million, up 239.03% from the prior year.
• Other financing activities was $158000.0 for Q1 2026 at BioXcel Therapeutics, up from $115000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $803000.0 in Q1 2025 to a low of $14000.0 in Q3 2024.
• Historically, Other financing activities has averaged $248727.3 across 4 years, with a median of $158000.0 in 2026.
• The sharpest annual moves came in 2024 and 2025: Other financing activities sank 84.17% in 2024, then soared 1614.29% in 2025.
• A 4-year view of Other financing activities shows it stood at $72000.0 in 2023, then soared by 148.61% to $179000.0 in 2024, then slumped by 35.75% to $115000.0 in 2025, then surged by 37.39% to $158000.0 in 2026.
• The last three Other financing activities figures came in at $158000.0 (Q1 2026), $115000.0 (Q4 2025), and $240000.0 (Q3 2025), per Business Quant data.